Clinical Trials Directory

Trials / Unknown

UnknownNCT02084615

Prospective Study Investigating Aspirin and Intraoperative Blood Loss and Complications Following Inguinal Hernia Repair

A Prospective, Nonrandomized, Study Comparing the Use of Aspirin and Intraoperative Blood Loss and Postoperative Complications Following Open Inguinal Hernia Repair.

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
300 (estimated)
Sponsor
Jesse Brown VA Medical Center · Federal
Sex
Male
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to determine whether aspirin taken in the perioperative period will increase the blood loss associated with open inguinal hernia repairs. A secondary purpose of this study is to determine if the aspirin administered in the perioperative period increases the risk of complications associated with open inguinal hernia repairs.

Detailed description

This is a prospective, non-randomized, study which compares the use of 81mg of aspirin, 325mg of aspirin or no aspirin in adult men undergoing an open tension free mesh inguinal hernia repair. Subjects currently taking 81mg or 325mg of aspirin will undergo inguinal hernia repair without having their medications stopped. Patient not currently taking aspirin will act as controls. Intraoperative blood loss will be measured utilizing a gravimetric method by weighing surgical sponges before and after use. Subjects will be followed for thirty days postoperatively and be evaluated for bleeding complications. The specific complications include wound or scrotal hematomas, return to the operating room within 72 hour for bleeding, wound infection, early recurrent hernia, excessive wound ecchymosis.

Conditions

Interventions

TypeNameDescription
DRUGAspirinSubjects will undergo open inguinal hernia repairs while taking their normal dose of 81mg, 325mg, or no aspirin

Timeline

Start date
2014-08-01
Primary completion
2016-08-01
Completion
2017-06-01
First posted
2014-03-12
Last updated
2015-06-18

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02084615. Inclusion in this directory is not an endorsement.